Abstract
Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 336-340 |
| Number of pages | 5 |
| Journal | American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics |
| Volume | 153 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Adverse drug reaction
- Antipsychotic medication
- Candidate gene association
- Genetic
- Schizophrenia
- Tardive dyskinesia
ASJC Scopus subject areas
- Genetics(clinical)
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
Cite this
A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. / Tsai, Huei Ting; Caroff, Stanley N.; Miller, Del D.; McEvoy, Joseph Patrick; Lieberman, Jeffrey A.; North, Kari E.; Scott Stroup, T.; Sullivan, Patrick F.
In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 153, No. 1, 01.01.2010, p. 336-340.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial
AU - Tsai, Huei Ting
AU - Caroff, Stanley N.
AU - Miller, Del D.
AU - McEvoy, Joseph Patrick
AU - Lieberman, Jeffrey A.
AU - North, Kari E.
AU - Scott Stroup, T.
AU - Sullivan, Patrick F.
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.
AB - Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.
KW - Adverse drug reaction
KW - Antipsychotic medication
KW - Candidate gene association
KW - Genetic
KW - Schizophrenia
KW - Tardive dyskinesia
UR - http://www.scopus.com/inward/record.url?scp=73949086059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949086059&partnerID=8YFLogxK
U2 - 10.1002/ajmg.b.30981
DO - 10.1002/ajmg.b.30981
M3 - Article
VL - 153
SP - 336
EP - 340
JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
SN - 1552-4841
IS - 1
ER -